Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer

BACKGROUND: Cancer immunotherapy has emerged as a promising strategy against triple-negative breast cancer (TNBC). One of the immunosuppressive pathways involves programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), but many patients derived little benefit from PD-1/PD-L1 checkp...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xintong, Tang, Lin, Chen, Qin, Cheng, Xumin, Liu, Yiqiu, Wang, Cenzhu, Zhu, Chengjun, Xu, Kun, Gao, Fangyan, Huang, Jinyi, Wang, Runtian, Guan, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945371/
https://www.ncbi.nlm.nih.gov/pubmed/36583862
http://dx.doi.org/10.1097/CM9.0000000000002329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945371/
https://www.ncbi.nlm.nih.gov/pubmed/36583862
http://dx.doi.org/10.1097/CM9.0000000000002329

Ejemplares similares